
  
    
      
        Introduction_NNP
        Elderly_JJ people_NNS show_VBP an_DT increased_VBN incidence_NN of_IN
        infectious_JJ ,_, neoplastic_JJ and_CC inflammatory_JJ diseases_NNS that_WDT may_MD
        be_VB linked_VBN to_TO declining_VBG functional_JJ competence_NN of_IN the_DT
        peripheral_JJ T_NN cells_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._. At_IN the_DT cellular_JJ level_NN ,_,
        this_DT decline_NN in_IN immune_JJ response_NN is_VBZ reflected_VBN in_IN aged_VBN T_NN cell_NN
        
        in_IN vitro_NN proliferation_NN ,_, decreased_VBD
        production_NN of_IN interleukin-_NN 2_CD [_NN 2_CD 6_CD 7_CD 8_CD ]_NN and_CC 11_CD -_: 2_CD receptor_NN [_NN
        7_CD 9_CD 10_CD ]_NN ,_, and_CC defective_JJ progression_NN thought_VBD the_DT cell_NN cycle_NN
        [_NN 11_CD 12_CD ]_NN ._. HIV_NNP +_NN infection_NN likewise_RB induces_VBZ a_DT progressive_JJ
        suppression_NN in_IN proliferation_NN of_IN both_DT CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS 
        in_IN vitro_NN that_IN correlates_NNS with_IN
        clinical_JJ severity_NN ,_, as_RB well_RB as_IN diminished_VBN 11_CD -_: 2_CD production_NN [_NN
        13_CD 14_CD 15_CD 16_CD ]_NN ._. However_RB ,_, even_RB stronger_JJR parallels_NNS exist_VBP
        between_IN immune_JJ phenomena_NNS in_IN aging_VBG and_CC AIDS_NNP than_IN suppression_NN
        of_IN T_NN cell_NN proliferation_NN and_CC 11_CD -_: 2_CD production_NN ._. There_EX is_VBZ a_DT
        relative_JJ increase_NN in_IN the_DT memory_NN cell_NN repertoire_NN [_NN 17_CD 18_CD 19_CD
        20_CD ]_NN ,_, and_CC an_DT increase_NN in_IN absolute_JJ counts_NNS in_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD
        -_: populations_NNS in_IN both_DT aged_VBN [_NN 22_CD ]_NN and_CC HIV_NNP +_NN donors_NNS [_NN 22_CD 23_CD 24_CD
        25_CD ]_NN ._. The_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN in_IN the_DT HIV_NNP +_NN state_NN appears_VBZ to_TO
        be_VB the_DT major_JJ cytotoxic_JJ T_NN cell_NN (_( CTL_NNP )_) [_NN 26_CD ]_NN ,_, but_CC curiously_RB ,_,
        has_VBZ shortened_VBN telemer_NN lengths_NNS as_RB well_RB [_NN 27_CD ]_NN ._.
        Previous_JJ studies_NNS indicate_VBP considerable_JJ inconsistency_NN
        regarding_VBG production_NN of_IN the_DT immune_JJ regulatory_JJ cytokine_NN ,_,
        interferon-γ_JJ (_( IFN-γ_NNP )_) and_CC the_DT preinflammatory_NN cytokine_NN ,_,
        tumor_NN necrosis_NNS factor-α_JJ (_( TNF-α_NNP )_) from_IN T_NN cells_NNS of_IN HFV_NNP +_NN and_CC
        aged_VBN individuals_NNS ._. The_DT disparity_NN in_IN IFN-γ_NNP expression_NN is_VBZ
        reflected_VBN in_IN reports_NNS of_IN decreased_VBD [_NN 28_CD 29_CD 30_CD 31_CD ]_NN ,_, normal_JJ
        [_NN 21_CD 32_CD ]_NN or_CC increased_VBN [_NN 33_CD 34_CD 35_CD 36_CD 37_CD ]_NN synthesis_NN in_IN both_DT
        aged_VBN and_CC HIV_NNP +_NN T_NN cells_NNS ._. Similarly_RB ,_, with_IN TNF-α_NNP ,_, there_EX are_VBP
        contradictory_JJ reports_NNS of_IN decreased_VBD [_NN 37_CD 38_CD ]_NN ,_, normal_JJ [_NN 29_CD
        ]_NN ,_, or_CC increased_VBD [_NN 12_CD 31_CD 39_CD 40_CD ]_NN production_NN in_IN the_DT HIV_NNP +_NN and_CC
        aged_VBN T_NN cells_NNS ._. Explanations_NNP for_IN the_DT divergent_JJ findings_NNS can_MD
        be_VB attributed_VBN to_TO many_JJ factors_NNS including_VBG cell_NN preparation_NN ,_,
        choice_NN of_IN activators_NNS ,_, and_CC quantitative_JJ methodology_NN ._.
        Recently_RB ,_, we_PRP showed_VBD [_NN 25_CD ]_NN that_IN IFN-γ_NNP production_NN in_IN HIV_NNP
        +_NN -_: derived_VBN CD_NNP 8_CD +_NN T_NN cells_NNS was_VBD strongly_RB stimulated_VBN by_IN upon_IN
        activation_NN anti-_NN CD_NNP 3_CD and_CC PMA_NNP ._. Using_VBG this_DT mode_NN of_IN activation_NN ,_,
        we_PRP selected_VBD flow_NN cytometry_NN for_IN analysis_NN of_IN HIV_NNP +_NN and_CC aged_VBN T_NN
        cells_NNS in_IN this_DT study_NN since_IN this_DT method_NN obviates_NNS the_DT inherent_JJ
        complications_NNS association_NN with_IN experimental_JJ variability_NN of_IN
        T_NN cell_NN purification_NN and_CC activation_NN ._. Subsequently_RB ,_, the_DT flow_NN
        cytometric_JJ data_NNS ,_, based_VBN on_IN the_DT percentage_NN of_IN active_JJ cells_NNS ,_,
        was_VBD supported_VBN by_IN cytokine_NN mRNA_NN and_CC ELISA_NNP data_NNS ._. We_PRP find_VBP by_IN
        all_DT three_CD methods_NNS that_IN IFN-γ_NNP and_CC TNF-α_NNP production_NN is_VBZ
        enhanced_VBN several_JJ fold_VB in_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN aged_VBN and_CC HIV_NNP
        +_NN individuals_NNS ,_, and_CC it_PRP is_VBZ the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: subset_NN ,_, as_IN shown_VBN by_IN
        flow_NN cytometry_NN ,_, which_WDT is_VBZ primarily_RB responsible_JJ ._. These_DT
        findings_NNS assume_VBP clinical_JJ importance_NN since_IN they_PRP may_MD explain_VB
        in_IN part_NN the_DT chronic_JJ and_CC autoimmune_JJ pathologies_NNS in_IN the_DT
        elderly_JJ ,_, particularly_RB rheumatoid_NN arthritis_NN ,_, Crohn_NNP 's_POS
        disease_NN ,_, sepsis_NN ,_, and_CC myelodysplastic_JJ syndromes_NNS ,_, which_WDT are_VBP
        exacerbated_VBN by_IN the_DT inflammatory_JJ cytokines_NNS IFN-γ_NNP and_CC TNF-α_NNP [_NN
        41_CD ]_NN ._. Likewise_RB ,_, the_DT elevation_NN of_IN these_DT cytokines_NNS ,_,
        particularly_RB TNF-α_NNP potentially_RB may_MD contribute_VB to_TO the_DT
        deterioration_NN in_IN the_DT HIV_NNP +_NN or_CC AIDS_NNP patient_NN by_IN promoting_VBG
        wasting_NN and_CC cachexia_NN [_NN 42_CD ]_NN ._.
      
      
        Results_NNS
        
          Enhanced_NNP IFN-γ_NNP and_CC TNF-α_NNP production_NN in_IN aged_VBN and_CC HIV_NNP
          +_NN CD_NNP 8_CD +_NN T_NN cells_NNS
          Representative_NNP examples_NNS of_IN the_DT cytometric_JJ profile_NN of_IN
          aged_VBN and_CC HIV_NNP +_NN human_JJ T_NN cells_NNS (_( CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN and_CC controls_NNS
          (_( normal_JJ young_JJ donors_NNS )_) are_VBP shown_VBN in_IN Fig_NNP ._. 1_LS ;_: the_DT cells_NNS
          producing_VBG IFN-γ_NNP and_CC TNF-α_NNP appear_VBP in_IN the_DT upper_JJ quadrants_NNS ._.
          The_DT percentages_NNS of_IN either_DT CD_NNP 4_CD +_NN or_CC CD_NNP 8_CD +_NN T_NN cells_NNS producing_VBG
          cytokine_NN (_( upper_JJ quadrant_NN )_) are_VBP shown_VBN ._. In_IN these_DT studies_NNS ,_,
          the_DT peripheral_JJ blood_NN mononuclear_NN cells_NNS (_( PBMC_NNP )_) were_VBD
          prepared_VBN and_CC activated_VBN for_IN 15_CD hrs_NNS with_IN anti-_NN CD_NNP 3_CD (_( plus_CC
          PMA_NNP )_) and_CC processed_VBN with_IN the_DT appropriate_JJ
          fluorescent-labeled_JJ antibodies_NNS ._. For_IN 3_CD color_NN FC_NNP analysis_NN ,_,
          the_DT samples_NNS were_VBD first_JJ gated_JJ for_IN the_DT CD_NNP 3_CD positive_JJ cells_NNS
          thus_RB eliminating_VBG B_NNP cells_NNS ,_, NK_NNP cells_NNS and_CC macrophages_NNS ,_, and_CC
          then_RB examined_VBD for_IN CD_NNP 8_CD +_NN and_CC cytokine-containing_JJ cells_NNS ._.
          Based_VBN on_IN past_JJ studies_NNS ,_, the_DT non_NN CD_NNP 8_CD +_NN T_NN cells_NNS are_VBP primarily_RB
          composed_VBN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS and_CC are_VBP designated_VBN as_IN such_JJ ._.
          Controls_NNP (_( not_RB shown_VBN )_) for_IN every_DT sample_NN were_VBD also_RB examined_VBN
          for_IN cytokine-producing_JJ cells_NNS (_( upper_JJ quadrants_NNS )_) in_IN which_WDT
          no_DT activators_NNS were_VBD added_VBN ;_: 0_CD ._. 0_CD -_: 0_CD ._. 6_CD %_NN positive_JJ cells_NNS were_VBD
          observed_VBN ._. Previously_RB we_PRP found_VBD [_NN 25_CD ]_NN that_DT activation_NN by_IN
          anti-_NN CD_NNP 3_CD and_CC PMA_NNP was_VBD far_RB superior_JJ to_TO other_JJ activation_NN
          modes_NNS such_JJ as_IN Con_NN A_DT plus_CC PMA_NNP in_IN stimulating_VBG IFN-γ_NNP
          synthesis_NN ._. Anti-_NNP CD_NNP 3_CD or_CC PMA_NNP alone_RB did_VBD not_RB induce_VB cytokine_NN
          production_NN [_NN 25_CD ]_NN ._. In_IN all_DT instances_NNS with_IN anti-_NN CD_NNP 28_CD as_IN
          coactivator_NN ,_, the_DT IFN-γ_NNP and_CC TNF-α_NNP responses_NNS were_VBD low_JJ ,_,
          rarely_RB exceeding_VBG 15_CD %_NN of_IN that_DT produced_VBN by_IN PMA_NNP /_NN anti-_NN CD_NNP 3_CD
          activation_NN ._.
          The_DT production_NN of_IN IFN-γ_NNP and_CC TNF-α_NNP from_IN aged_VBN and_CC HIV_NNP +_NN T_NN
          cells_NNS (_( CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN )_) activated_VBN by_IN anti-_NN CD_NNP 3_CD and_CC PMA_NNP is_VBZ
          shown_VBN in_IN Table_NNP I_PRP ._. The_DT data_NNS were_VBD derived_VBN from_IN the_DT flow_NN
          cytometric_JJ analysis_NN of_IN the_DT CD_NNP 8_CD +_NN and_CC CD_NNP 4_CD +_NN T_NN cell_NN profiles_NNS
          of_IN forty_NN aged_VBN ,_, thirty-two_JJ HIV_NNP +_NN and_CC forty-eight_JJ normal_JJ
          young_JJ donors_NNS ._. Experiments_NNS with_IN the_DT HrV_NNP +_NN -_: derived_VBN cells_NNS
          were_VBD performed_VBN separately_RB from_IN those_DT with_IN aged_VBN cells_NNS with_IN
          24_CD control_NN donors_NNS used_VBN in_IN each_DT case_NN ._. The_DT cytokine_NN
          analysis_NN relies_VBZ on_IN the_DT intracellular_NN accumulation_NN of_IN
          cytokines_NNS in_IN the_DT Golgi_NNP compartment_NN over_IN the_DT 15_CD hr_NN ._.
          activation_NN period_NN induced_VBN by_IN either_DT brefeldin_NN A_DT or_CC
          monensin_NN ._. Both_DT inhibitors_NNS block_VBP Golgi_NNP function_NN and_CC thus_RB
          cytokine_NN secretion_NN ,_, the_DT former_NN by_IN inhibition_NN of_IN protein_NN
          vesicle_NN transport_NN [_NN 43_CD ]_NN ,_, the_DT latter_NN by_IN inhibition_NN of_IN Na_NNP
          +_NN gradients_NNS [_NN 44_CD ]_NN ._.
          Flow_NNP cytometric_JJ analysis_NN of_IN cells_NNS from_IN the_DT aged_VBN donors_NNS
          activated_VBN by_IN anti-_NN CD_NNP 3_CD and_CC PMA_NNP shows_VBZ that_IN IFN-γ_NNP production_NN
          is_VBZ enhanced_VBN significantly_RB (_( approximately_RB 3_CD fold_VB )_) in_IN the_DT
          CD_NNP 8_CD +_NN T_NN cell_NN compartment_NN ,_, in_IN terms_NNS of_IN percent_NN of_IN producing_VBG
          cells_NNS ,_, compared_VBN to_TO young_JJ control_NN donors_NNS (_( Table_NNP I_PRP )_) ._. Even_RB
          with_IN Con_NN A_DT and_CC PMA_NNP activation_NN ,_, the_DT aged_VBN CD_NNP 8_CD +_NN T_NN cell_NN
          response_NN was_VBD 4_CD fold_VB enhanced_VBN over_IN young_JJ controls_NNS (_( 28_CD ._. 0_CD %_NN
          and_CC 7_CD ._. 0_CD %_NN respectively_RB )_) (_( data_NNS not_RB shown_VBN )_) ._. The_DT response_NN of_IN
          brefeldin-treated_JJ CD_NNP 8_CD +_NN cells_NNS was_VBD somewhat_RB greater_JJR than_IN in_IN
          the_DT monensin-treated_JJ cells_NNS ,_, for_IN both_DT aged_VBN and_CC controls_NNS ._.
          For_IN the_DT HiV_NNP +_NN group_NN ,_, the_DT number_NN of_IN IFN-γ_NNP producing_VBG CD_NNP 8_CD +_NN T_NN
          cells_NNS was_VBD similarly_RB enhanced_VBN over_IN normal_JJ controls_NNS with_IN
          both_DT types_NNS of_IN Golgi_NNP inhibitors_NNS ._. Interestingly_RB ,_, although_IN
          the_DT CD_NNP 4_CD +_NN T_NN cell_NN is_VBZ a_DT target_NN for_IN the_DT HIV_NNP ,_, the_DT IFN-γ_NNP
          response_NN is_VBZ not_RB significantly_RB changed_VBN from_IN the_DT normal_JJ CD_NNP 4_CD
          +_NN T_NN cell_NN response_NN ._. Likewise_RB ,_, with_IN the_DT aged_VBN CD_NNP 4_CD +_NN cells_NNS ,_,
          there_EX is_VBZ no_DT significant_JJ difference_NN with_IN the_DT responses_NNS of_IN
          the_DT cells_NNS from_IN young_JJ donors_NNS ._.
          The_DT changes_NNS in_IN TNF-α_NNP production_NN in_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN
          HIV_NNP +_NN and_CC aged_VBN individuals_NNS are_VBP comparable_JJ to_TO that_DT for_IN
          IFN-γ_NNP production_NN (_( Fig_NNP ._. 1_LS and_CC Table_NNP I_PRP )_) ._. Aged_NNP CD_NNP 8_CD +_NN T_NN cells_NNS
          show_VBP a_DT significant_JJ increase_NN (_( approximately_RB 3_CD fold_VB )_) over_IN
          young_JJ cells_NNS in_IN the_DT percentage_NN producing_VBG TNF-α_NNP (_( 57_CD ._. 6_CD
          versus_CC 19_CD ._. 0_CD %_NN )_) ._. In_IN the_DT HIV_NNP +_NN cases_NNS also_RB ,_, the_DT CD_NNP 8_CD +_NN T_NN cells_NNS
          show_VBP significantly_RB enhanced_VBD TNF-α_NNP production_NN (_( 2_CD fold_VB )_) ._.
          However_RB ,_, in_IN contrast_NN to_TO the_DT IFN-γ_NNP data_NN ,_, the_DT aged_VBN CD_NNP 4_CD +_NN T_NN
          cells_NNS are_VBP modestly_RB ,_, but_CC significantly_RB increased_VBN over_IN the_DT
          young_JJ CD_NNP 4_CD +_NN T_NN cells_NNS (_( 50_CD ._. 3_LS versus_CC 35_CD ._. 9_CD %_NN )_) ._. The_DT CD_NNP 4_CD +_NN T_NN cells_NNS
          from_IN HIV_NNP +_NN donors_NNS also_RB are_VBP slightly_RB more_RBR capable_JJ of_IN TNF-α_NNP
          production_NN than_IN the_DT normal_JJ CD_NNP 4_CD +_NN T_NN cells_NNS (_( 51_CD ._. 0_CD versus_CC
          42_CD ._. 0_CD %_NN )_) ,_, a_DT difference_NN that_WDT is_VBZ significant_JJ ._. Thus_RB in_IN the_DT
          aging_VBG and_CC HIV_NNP +_NN scenario_NN ,_, it_PRP is_VBZ apparent_JJ that_IN the_DT CD_NNP 8_CD +_NN T_NN
          cells_NNS show_VBP an_DT enhanced_JJ capacity_NN for_IN both_DT TNF-α_NNP production_NN
          and_CC IFN-γ_NNP production_NN ._. The_DT CD_NNP 4_CD +_NN T_NN cells_NNS show_VBP a_DT small_JJ but_CC
          significant_JJ capacity_NN for_IN TNF-α_NNP production_NN in_IN both_DT
          scenarios_NNS ._.
        
        
          Comparative_NNP analysis_NN of_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: and_CC CD_NNP 8_CD
          +_NN CD_NNP 28_CD +_NN T_NN cells_NNS by_IN flow_NN cytometry_NN
          For_IN each_DT blood_NN sample_NN ,_, a_DT non-activated_JJ control_NN was_VBD
          prepared_VBN in_IN which_WDT the_DT PBMC_NNP were_VBD incubated_JJ in_IN the_DT absence_NN
          of_IN activators_NNS (_( anti-_NN CD_NNP 3_CD and_CC PMA_NNP )_) ,_, and_CC then_RB examined_VBN by_IN
          flow_NN cytometry_NN ._. Such_JJ controls_NNS showed_VBD no_DT significant_JJ
          cytokine-containing_JJ cells_NNS ,_, and_CC these_DT samples_NNS were_VBD used_VBN to_TO
          calculate_VB the_DT resting_VBG CD_NNP 4_CD +_NN /_NN CD_NNP 8_CD +_NN distribution_NN and_CC the_DT
          CD_NNP 28_CD +_NN /_NN CD_NNP 28_CD -_: distribution_NN ._. As_IN shown_VBN in_IN Table_NNP III_NNP ,_, there_EX
          is_VBZ a_DT dramatic_JJ phenotypic_JJ change_NN in_IN the_DT CD_NNP 8_CD +_NN subsets_NNS in_IN
          the_DT aged_VBN and_CC HIV_NNP states_NNS in_IN relation_NN to_TO young_JJ healthy_JJ
          controls_NNS ._. In_IN our_PRP$ IFN-γ_NNP studies_NNS ,_, the_DT CD_NNP 28_CD -_: population_NN
          accounts_NNS for_IN 61_CD ._. 3_LS %_NN (_( aged_VBN )_) to_TO 70_CD ._. 0_CD %_NN (_( HIV_NNP +_NN )_) of_IN the_DT total_JJ
          CD_NNP 8_CD +_NN population_NN ._. In_IN healthy_JJ controls_NNS ,_, the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD
          -_: subset_NN accounts_NNS for_IN only_RB 28_CD -_: 31_CD %_NN of_IN the_DT CD_NNP 8_CD +_NN cells_NNS ._. In_IN
          the_DT TNF-α_NNP studies_NNS ,_, the_DT CD_NNP 28_CD -_: cells_NNS are_VBP 64_CD ._. 2_LS %_NN (_( aged_VBN )_) to_TO
          68_CD ._. 3_LS %_NN (_( HIV_NNP +_NN )_) of_IN the_DT total_JJ CD_NNP 8_CD +_NN population_NN ._. The_DT TNF-α_NNP and_CC
          IFN-γ_NNP studies_NNS were_VBD carried_VBN out_IN separately_RB ._. These_DT results_NNS
          indicate_VBP that_IN in_IN the_DT HIV_NNP +_NN and_CC aged_VBN states_NNS ,_, the_DT CD_NNP 28_CD
          -_: subset_NN becomes_VBZ dominant_JJ ,_, assuming_VBG approximately_RB
          two-thirds_NNS of_IN the_DT total_JJ CD_NNP 8_CD +_NN cells_NNS whereas_IN in_IN the_DT normal_JJ
          healthy_JJ state_NN the_DT CD_NNP 28_CD +_NN T_NN cell_NN subset_NN accounts_NNS for_IN
          approximately_RB two-thirds_NNS ._. Thus_RB ,_, in_IN terms_NNS of_IN cell_NN numbers_NNS ,_,
          the_DT CD_NNP 28_CD -_: cells_NNS constitute_VBP the_DT majority_NN of_IN the_DT CD_NNP 8_CD +_NN T_NN
          cells_NNS and_CC explains_VBZ our_PRP$ previous_JJ findings_NNS (_( 16_CD ,_, 45_CD )_) that_IN the_DT
          mitogenic_JJ signal_NN arising_VBG from_IN coactivation_NN by_IN anti-_NN CD_NNP 28_CD
          was_VBD greatly_RB suppressed_VBN in_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN HIV_NNP +_NN donors_NNS
          compared_VBN to_TO normal_JJ donors_NNS ._.
          The_DT data_NNS (_( Table_NNP III_NNP )_) show_NN that_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cells_NNS
          also_RB account_VBP for_IN the_DT increased_VBN production_NN of_IN TNF-α_NNP and_CC
          IFN-γ_NNP in_IN both_DT the_DT HIV_NNP +_NN and_CC aged_VBN states_NNS ._. In_IN these_DT states_NNS ,_,
          the_DT percent_NN of_IN CD_NNP 28_CD -_: cells_NNS producing_VBG each_DT cytokine_NN
          dominates_VBZ the_DT normal_JJ young_JJ controls_NNS by_IN a_DT 2_CD :_: 1_CD to_TO 3_CD :_: 1_CD
          margin_NN ._. Thus_RB not_RB only_RB are_VBP the_DT CD_NNP 28_CD -_: cells_NNS greater_JJR in_IN
          number_NN ,_, but_CC they_PRP are_VBP proportionately_RB much_RB more_RBR active_JJ in_IN
          cytokine_NN production_NN ._. As_IN a_DT consequence_NN ,_, the_DT data_NNS show_VBP that_IN
          the_DT CD_NNP 28_CD -_: population_NN accounts_NNS for_IN the_DT majority_NN of_IN the_DT
          cytokine-producing_JJ CD_NNP 8_CD +_NN T_NN cells_NNS (_( 79_CD ._. 6_CD -_: 86_CD ._. 7_CD %_NN )_) in_IN the_DT HIV_NNP
          +_NN and_CC aged_VBN populations_NNS ._. Typical_JJ examples_NNS of_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD
          -_: profiles_NNS are_VBP shown_VBN in_IN Fig_NNP ._. 2_LS ._. It_PRP is_VBZ evident_JJ that_IN the_DT
          cells_NNS from_IN the_DT HIV_NNP +_NN and_CC aged_VBN states_NNS have_VBP a_DT greater_JJR
          capacity_NN for_IN TNF-α_NNP and_CC IFN-γ_NNP production_NN compared_VBN to_TO the_DT
          normal_JJ control_NN CD_NNP 28_CD -_: or_CC CD_NNP 28_CD +_NN population_NN ._.
        
        
          Production_NN of_IN other_JJ cytokines_NNS (_( I_NN 1_CD -_: 2_CD ,_, 4_CD ,_, 6_CD and_CC
          10_CD )_)
          The_DT ability_NN of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS from_IN aged_VBN and_CC HIV_NNP
          +_NN donors_NNS to_TO synthesize_VB 11_CD -_: 2_CD ,_, 11_CD -_: 4_CD ,_, 11_CD -_: 6_CD and_CC 11_CD -_: 10_CD were_VBD
          also_RB studied_VBN by_IN flow_NN cytometry_NN ._. Only_RB in_IN the_DT case_NN of_IN 11_CD -_: 2_CD
          was_VBD an_DT appreciable_JJ number_NN of_IN cytokine-producing_JJ cells_NNS
          observed_VBD [_NN 25_CD ]_NN ._. For_IN normal_JJ young_JJ cells_NNS at_IN least_JJS 15_CD -_: 30_CD %_NN
          of_IN CD_NNP 4_CD +_NN cells_NNS were_VBD positive_JJ for_IN 11_CD -_: 2_CD while_IN only_RB 3_CD -_: 6_CD %_NN of_IN
          the_DT CD_NNP 8_CD +_NN cells_NNS were_VBD positive_JJ ._. With_IN HIV_NNP +_NN and_CC aged_VBN T_NN cells_NNS ,_,
          there_EX was_VBD a_DT significant_JJ 11_CD -_: 2_CD response_NN also_RB ,_, but_CC it_PRP was_VBD
          generally_RB smaller_JJR than_IN from_IN the_DT young_JJ normal_JJ control_NN
          cells_NNS (_( data_NNS not_RB shown_VBN )_) ._. The_DT percentage_NN of_IN cells_NNS positive_JJ
          for_IN production_NN of_IN 11_CD -_: 4_CD ,_, 11_CD -_: 6_CD and_CC 11_CD -_: 10_CD was_VBD extremely_RB low_JJ ._.
          The_DT number_NN of_IN productive_JJ cells_NNS was_VBD often_RB <_NN 1_CD %_NN and_CC only_RB
          rarely_RB exceeded_VBD 2_CD %_NN of_IN either_DT the_DT CD_NNP 4_CD +_NN or_CC CD_NNP 8_CD +_NN population_NN ._.
          No_DT significant_JJ difference_NN was_VBD observed_VBN between_IN the_DT
          control_NN cells_NNS and_CC those_DT derived_VBN from_IN HIV_NNP +_NN or_CC aged_VBN
          donors_NNS ._.
        
        
          Production_NN of_IN IFN-γ_NNP and_CC TNF-α_NNP mRNA_NN determined_VBN by_IN
          Quantitative_NNP PCR_NNP
          The_DT mRNA_NN isolated_VBN from_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN 12_CD aged_VBN ,_, 10_CD
          HIV_NNP +_NN and_CC 15_CD controls_NNS were_VBD purified_JJ and_CC used_VBN in_IN these_DT
          studies_NNS ._. The_DT results_NNS ,_, shown_VBN in_IN Fig_NNP 3_CD are_VBP expressed_VBN as_IN
          IFN-γ_NNP (_( or_CC TNF-α_NNP )_) cDNA_NN copies_NNS /_NN ug_NN total_JJ RNA_NNP ._. CD_NNP 8_CD +_NN T_NN cells_NNS
          were_VBD incubated_JJ for_IN 3_CD hrs_NNS with_IN PMA_NNP and_CC anti-_NN CD_NNP 3_CD prior_RB to_TO
          total_VB RNA_NNP extraction_NN ._. For_IN IFN-γ_NNP ,_, CD_NNP 8_CD +_NN T_NN cells_NNS from_IN both_DT
          the_DT HIV_NNP +_NN and_CC aged_VBN states_NNS show_VBP a_DT 4_CD ._. 5_CD -_: 5_CD fold_VB enhancement_NN in_IN
          cDNA_NN copies_NNS (_( 32_CD ,_, 000_CD and_CC 47_CD ,_, 000_CD respectively_RB versus_CC
          controls_NNS of_IN 7_CD ,_, 400_CD and_CC 9_CD ,_, 100_CD )_) ._. Likewise_RB ,_, the_DT TNF-α_NNP cDNA_NN
          copies_NNS are_VBP enhanced_VBN approximately_RB 4_CD fold_VB in_IN the_DT CD_NNP 8_CD +_NN T_NN
          cells_NNS from_IN aged_VBN and_CC HIV_NNP +_NN states_NNS ._. In_IN view_NN of_IN the_DT flow_NN
          cytometric_JJ data_NNS ,_, we_PRP can_MD infer_NN that_IN the_DT enhanced_JJ mRNA_NN in_IN
          the_DT CD_NNP 8_CD +_NN T_NN cells_NNS derives_VBZ primarily_RB from_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN
          cells_NNS ._.
        
        
          Secreted_NNP IFN-γ_NNP and_CC TNF-α_NNP determined_VBN by_IN ELISA_NNP
          The_DT PBMC_NNP and_CC purified_JJ CD_NNP 8_CD +_NN T_NN cells_NNS from_IN eight_CD donors_NNS
          and_CC seven_CD control_NN donors_NNS were_VBD incubated_JJ for_IN 66_CD hrs_NNS ,_, and_CC
          the_DT media_NNS examined_VBN by_IN ELISA_NNP ._. The_DT results_NNS ,_, shown_VBN in_IN Table_NNP
          III_NNP ,_, demonstrate_VB that_DT production_NN of_IN IFN-γ_NNP is_VBZ upregulated_JJ
          over_IN controls_NNS ,_, from_IN 3_CD ._. 5_CD -_: 4_CD fold_VB ,_, for_IN the_DT CD_NNP 8_CD +_NN T_NN cells_NNS from_IN
          HIV_NNP +_NN and_CC aged_VBN donors_NNS ._. For_IN TNF-α_NNP ,_, the_DT increase_NN was_VBD also_RB
          substantial_JJ ,_, 2_CD ._. 3_CD -_: 4_CD fold_VB ._.
        
      
      
        Discussion_NNP
        Our_PRP$ data_NNS show_VBP that_IN the_DT HIV_NNP +_NN and_CC aged_VBN conditions_NNS foster_VB a_DT
        change_NN in_IN the_DT CD_NNP 8_CD +_NN T_NN cell_NN repertoire_NN characterized_VBN by_IN
        expansion_NN of_IN a_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: phenotype_NN capable_JJ of_IN enhanced_VBN
        IFN-γ_NNP and_CC TNF-α_NNP production_NN ._. These_DT results_NNS contrast_VBP with_IN
        other_JJ studies_NNS concluding_VBG that_IN the_DT production_NN of_IN these_DT
        cytokines_NNS was_VBD downregulated_JJ or_CC unchanged_JJ in_IN T_NN cells_NNS from_IN
        HIV_NNP +_NN and_CC aged_VBN individuals_NNS [_NN 21_CD 28_CD 29_CD 30_CD 31_CD 32_CD 37_CD 38_CD ]_NN ._.
        Reliability_NNP in_IN our_PRP$ findings_NNS derives_VBZ from_IN use_NN of_IN flow_NN
        cytometric_JJ analysis_NN which_WDT measures_NNS 
        de_IN novo_NN synthesis_NN per_IN cell_NN and_CC thus_RB
        obviates_NNS numerous_JJ artifacts_NNS possibly_RB associated_VBN with_IN ELISA_NNP
        or_CC procedures_NNS that_WDT measure_NN mRNA_NN synthesis_NN ._. Secondly_RB ,_,
        similar_JJ results_NNS were_VBD obtained_VBN with_IN two_CD different_JJ inhibitors_NNS
        of_IN Golgi_NNP transport_NN ._. Thirdly_NNP ,_, of_IN the_DT cytokines_NNS examined_VBD ,_,
        including_VBG 11_CD -_: 4_CD ,_, 11_CD -_: 6_CD and_CC 11_CD -_: 10_CD ,_, only_RB IFN-γ_NNP and_CC TNF-α_NNP were_VBD
        enhanced_VBN in_IN the_DT HIV_NNP +_NN or_CC aged_VBN states_NNS ._. Fourthly_NNP ,_, CD_NNP 4_CD +_NN T_NN cells_NNS
        did_VBD not_RB show_VB a_DT significant_JJ change_NN in_IN IFN-γ_NNP production_NN ,_, but_CC
        did_VBD show_NN a_DT small_JJ but_CC significant_JJ increase_NN in_IN TNF-α_NNP
        production_NN in_IN aged_VBN and_CC HIV_NNP +_NN -_: derived_VBN cells_NNS ._. Fifthly_NNP ,_, the_DT
        mRNA_NN and_CC ELISA_NNP studies_NNS support_VBP the_DT conclusions_NNS of_IN the_DT flow_NN
        cytometric_JJ data_NNS ._.
        The_DT question_NN arises_VBZ whether_IN or_CC not_RB our_PRP$ results_NNS have_VBP
        physiological_JJ relevance_NN since_IN PMA_NNP and_CC anti-_NN CD_NNP 3_CD was_VBD used_VBN to_TO
        elicit_NN the_DT cytokine_NN responses_NNS we_PRP observed_VBD ._. The_DT question_NN
        resolves_NNS into_IN two_CD parts_NNS :_: are_VBP TNF-α_NNP and_CC IFN-γ_NNP levels_NNS
        increased_VBN in_IN the_DT HIV_NNP +_NN and_CC aged_VBN states_NNS ,_, and_CC do_VBP the_DT CD_NNP 8_CD +_NN T_NN
        cells_NNS show_VBP increased_VBN production_NN of_IN these_DT cytokines_NNS ._. There_EX
        is_VBZ considerable_JJ evidence_NN supporting_VBG both_DT parts_NNS of_IN this_DT
        question_NN ._. Regarding_VBG part_NN one_CD ,_, IFN-γ_NNP levels_NNS are_VBP elevated_VBD in_IN
        the_DT sera_NN of_IN HIV_NNP +_NN patients_NNS [_NN 45_CD ]_NN ._. Serum_NNP levels_NNS of_IN both_DT
        TNF-α_NNP and_CC IFN-γ_NNP were_VBD markedly_RB higher_JJR in_IN HIV_NNP +_NN patients_NNS over_IN
        controls_NNS ,_, but_CC varied_VBD depending_VBG on_IN the_DT skin_NN disease_NN
        exhibited_VBN by_IN the_DT patient_NN [_NN 46_CD ]_NN ._. AIDS_NNP patients_NNS also_RB showed_VBD
        elevated_VBD TNF-α_NNP levels_NNS in_IN the_DT plasma_NN [_NN 47_CD ]_NN ._. Studies_NNPS of_IN
        lymphocytes_NNS from_IN aged_VBN donors_NNS showed_VBD increase_NN serum_NN levels_NNS
        of_IN TNF-α_NNP and_CC IFN-γ_NNP that_WDT correlate_VBP with_IN upregulation_NN of_IN
        HLA-DR_NNP on_IN CD_NNP 3_CD +_NN -_: lymphocytes_NNS [_NN 48_CD ]_NN ._.
        Regarding_VBG part_NN two_CD ,_, there_EX are_VBP many_JJ studies_NNS showing_VBG that_IN
        physiological_JJ activation_NN of_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN HIV_NNP +_NN or_CC aged_VBN
        donors_NNS prompts_VBZ increased_VBN IFN-γ_NNP and_CC /_NN or_CC TNF-α_NNP production_NN ._. HIV_NNP
        +_NN lymph_NN nodes_NNS exhibit_NN a_DT large_JJ (_( 6_CD fold_VB )_) increase_NN in_IN CD_NNP 8_CD +_NN T_NN
        cells_NNS ,_, most_JJS of_IN which_WDT are_VBP involved_VBN in_IN IFN-γ_NNP production_NN [_NN 49_CD
        ]_NN ._. Amison_NNP et_CC al_NN [_NN 50_CD ]_NN concluded_VBD that_IN IFN-γ_NNP is_VBZ secreted_JJ by_IN
        the_DT CD_NNP 8_CD +_NN T_NN cell_NN in_IN HIV_NNP +_NN infections_NNS ._. In_IN CD_NNP 8_CD +_NN T_NN cells_NNS from_IN
        African_NNP HIV_NNP +_NN patients_NNS ,_, stimulated_VBN with_IN env_NN peptide_NN ,_, both_DT
        IFN-γ_NNP and_CC TNF-α_NNP production_NN were_VBD increased_VBN over_IN controls_NNS [_NN
        52_CD ]_NN ._. PBMC_NNP from_IN the_DT elderly_JJ (_( almost_RB healthy_JJ donors_NNS )_) showed_VBD
        upregulation_NN of_IN TNF-α_NNP in_IN unstimulated_JJ cultures_NNS [_NN 52_CD ]_NN ._.
        HLA-DR_NNP activation_NN of_IN CD_NNP 8_CD +_NN CD_NNP 57_CD +_NN cells_NNS from_IN elderly_JJ subjects_NNS
        strongly_RB produced_VBN TNF-α_NNP [_NN 48_CD ]_NN ._.
        Lipopolysaccharide-activation_NNP of_IN T_NN cells_NNS from_IN aged_VBN donors_NNS
        induced_VBD higher_JJR levels_NNS of_IN TNF-α_NNP than_IN controls_NNS in_IN two_CD
        separate_JJ studies_NNS [_NN 53_CD 31_CD ]_NN ._. Finally_RB ,_, in_IN HIV_NNP +_NN patients_NNS
        receiving_VBG HIV_NNP type_NN 1_CD antigen_NN ,_, both_DT INF-γ_NNP and_CC TNF-α_NNP were_VBD
        significantly_RB increased_VBN in_IN memory_NN T_NN cells_NNS activated_VBN by_IN
        antigen_NN [_NN 54_CD ]_NN ._.
        Thus_RB there_EX appears_VBZ to_TO be_VB considerable_JJ support_NN for_IN the_DT
        enhanced_JJ presence_NN of_IN TNF-α_NNP and_CC INF-γ_NNP in_IN the_DT HIV_NNP +_NN and_CC the_DT
        aged_VBN states_NNS ,_, and_CC for_IN a_DT physiologic_JJ role_NN of_IN the_DT CD_NNP 8_CD +_NN T_NN cell_NN
        subset_NN in_IN their_PRP$ production_NN ._. Our_PRP$ data_NNS shows_VBZ that_IN it_PRP is_VBZ the_DT
        CD_NNP 8_CD +_NN CD_NNP 28_CD -_: cell_NN that_WDT is_VBZ primarily_RB responsible_JJ ._. Why_WRB the_DT CD_NNP 8_CD
        +_NN CD_NNP 28_CD -_: subset_NN should_MD dominated_VBN in_IN such_JJ apparently_RB diverse_JJ
        conditions_NNS as_IN the_DT HIV_NNP +_NN and_CC the_DT aged_VBN states_NNS is_VBZ not_RB known_VBN ._.
        However_RB ,_, the_DT notion_NN that_IN similarities_NNS exist_VBP between_IN the_DT HIV_NNP
        +_NN and_CC the_DT aged_VBN states_NNS with_IN respect_NN to_TO the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN
        has_VBZ been_VBN presented_VBN previously_RB [_NN 55_CD ]_NN ._. It_PRP has_VBZ also_RB been_VBN
        proposed_VBN that_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN in_IN the_DT HIV_NNP +_NN state_NN is_VBZ
        derived_VBN from_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD +_NN cells_NNS by_IN clonal_NN expansion_NN
        induced_VBN by_IN massive_JJ antigenic_JJ stimulus_NN (_( HIV_NNP proteins_NNS )_) since_IN
        both_DT showed_VBN the_DT same_JJ epitope_NN repertoire_NN [_NN 26_CD ]_NN ._. Dolad_NNP et_CC
        al_NN [_NN 56_CD ]_NN have_VBP shown_VBN that_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: cell_NN ,_, not_RB the_DT CD_NNP 8_CD
        +_NN CD_NNP 28_CD +_NN cell_NN ,_, comprises_VBZ the_DT major_JJ CTL_NNP activity_NN in_IN the_DT HIV_NNP
        +_NN state_NN ,_, a_DT finding_VBG confirmed_VBN by_IN Vingerhoets_NNP et_CC al_NN [_NN 57_CD ]_NN ,_,
        who_WP associated_VBN cytotoxic_JJ T_NN cell_NN activity_NN with_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD
        -_: T_NN cell_NN in_IN HIV-infected_NNP subjects_NNS ._. Thus_RB ,_, the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN
        cell_NN assumes_VBZ a_DT crucial_JJ role_NN in_IN HIV_NNP infection_NN ._. Likewise_RB in_IN
        the_DT aged_VBN state_NN ,_, we_PRP can_MD speculate_VB that_IN chronic_JJ viral_JJ and_CC
        bacterial_JJ exposure_NN over_IN a_DT lifetime_NN may_MD induce_VB the_DT clonal_NN
        expansion_NN of_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN ._.
        There_EX is_VBZ evidence_NN that_IN the_DT cytotoxic_JJ activity_NN of_IN the_DT
        CD_NNP 28_CD -_: cell_NN can_MD lyse_NN and_CC suppress_VB HIV-infected_NNP cells_NNS [_NN 58_CD 59_CD
        ]_NN and_CC thus_RB play_VB a_DT protective_JJ role_NN in_IN HIV_NNP infection_NN ._. Perhaps_RB
        in_IN the_DT aged_VBN cell_NN as_IN well_RB ,_, the_DT CD_NNP 28_CD -_: memory_NN cell_NN serves_VBZ a_DT
        similar_JJ protective_JJ role_NN against_IN a_DT variety_NN of_IN viruses_NNS ._. The_DT
        production_NN of_IN IFN-γ_NNP and_CC TNF-α_NNP can_MD result_VB in_IN strong_JJ
        anti-viral_JJ consequences_NNS as_IN shown_VBN with_IN hepatitis_NNP B_NNP virus_NN [_NN
        60_CD ]_NN ,_, but_CC the_DT cytokines_NNS have_VBP a_DT dual_JJ role_NN since_IN they_PRP are_VBP
        associated_VBN with_IN inflammatory_JJ activity_NN ._. IFN-γ_NNP ,_, in_IN its_PRP$
        defensive_JJ role_NN against_IN infection_NN ,_, is_VBZ a_DT foremost_JJ factor_NN in_IN
        converting_VBG resting_VBG macrophages_NNS into_IN the_DT active_JJ state_NN [_NN 61_CD ]_NN
        where_WRB they_PRP produce_VBP reactive_JJ oxidants_NNS [_NN 62_CD ]_NN ,_, nitric_JJ oxide_NN
        [_NN 63_CD ]_NN ,_, TNF-α_NNP [_NN 61_CD ]_NN ,_, and_CC neopterin_NN ._. Not_RB only_RB can_MD these_DT
        factors_NNS damage_VBP DNA_NNP and_CC host_NN tissues_NNS but_CC can_MD modulate_VBP
        inflammatory_JJ reactions_NNS [_NN 60_CD ]_NN and_CC stimulate_VB apoptosis_NNS [_NN 64_CD
        ]_NN ,_, a_DT major_JJ mechanism_NN leading_VBG to_TO loss_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS [_NN 65_CD
        ]_NN ._. TNF-α_NNP also_RB has_VBZ the_DT capacity_NN to_TO perturb_NN the_DT clinical_JJ
        condition_NN in_IN AIDS_NNP by_IN strongly_RB upregulating_VBG the_DT
        transcription_NN of_IN the_DT HIV_NNP genome_NN [_NN 66_CD ]_NN ._. In_IN fact_NN ,_, it_PRP has_VBZ
        been_VBN proposed_VBN [_NN 67_CD ]_NN that_IN AIDS_NNP is_VBZ in_IN many_JJ ways_NNS a_DT TNF-α_NNP
        disease_NN since_IN this_DT cytokine_NN it_PRP is_VBZ a_DT potent_JJ activator_NN of_IN
        NF-kB_NNP ,_, and_CC an_DT inducer_NN of_IN HIV_NNP genome_NN transcription_NN and_CC
        apoptosis_NNS in_IN HIV-infected_NNP T_NN cells_NNS ._. Moreover_RB ,_, the_DT wasting_NN ,_,
        weight_NN loss_NN ,_, and_CC cachexia_NN associated_VBN with_IN AIDS_NNP has_VBZ also_RB
        been_VBN related_VBN to_TO TNF-α_NNP activity_NN [_NN 42_CD ]_NN ._. Thus_RB both_DT IFN-γ_NNP and_CC
        TNF-α_NNP have_VBP the_DT potential_NN for_IN a_DT double_JJ role_NN in_IN the_DT
        pathogenesis_NNS associated_VBN with_IN AIDS_NNP i_NNP ._. e_SYM ._. antiviral_JJ and_CC
        inflammatory_JJ responses_NNS ._.
        Based_VBN on_IN the_DT AIDS_NNP scenario_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO propose_VB
        that_IN chronic_JJ viral_JJ and_CC bacterial_JJ infections_NNS suffered_VBN by_IN an_DT
        individual_NN over_IN a_DT lifetime_NN may_MD lead_VB to_TO similar_JJ consequences_NNS
        as_IN those_DT occurring_VBG in_IN acute_JJ HIV_NNP infection_NN ,_, i_NNP ._. e_SYM ._. ,_, clonal_NN
        expansion_NN of_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: subset_NN at_IN the_DT expense_NN of_IN the_DT
        CD_NNP 8_CD +_NN CD_NNP 28_CD -_: subset_NN ._. The_DT data_NNS argue_VBP that_IN the_DT CD_NNP 28_CD -_: cell_NN may_MD
        serve_VB as_IN a_DT natural_JJ endpoint_NN in_IN the_DT differentiation_NN of_IN CD_NNP 8_CD
        +_NN cells_NNS ,_, as_IN proposed_VBN by_IN Effros_NNP et_CC al_NN [_NN 27_CD ]_NN ,_, where_WRB aging_VBG
        represents_VBZ a_DT "_'' normal_JJ endpoint_NN "_'' that_WDT occurs_VBZ after_IN many_JJ years_NNS
        of_IN immune_JJ activity_NN ,_, while_IN AIDS_NNP represents_VBZ an_DT accelerated_VBN
        endpoint_NN due_JJ to_TO the_DT increase_NN rate_NN in_IN T_NN cell_NN formation_NN
        during_IN attempted_JJ compensation_NN for_IN CD_NNP 4_CD +_NN loss_NN induced_VBN by_IN HIV_NNP ._.
        By_IN virtue_NN of_IN their_PRP$ inflammatory_JJ roles_NNS ,_, TNF-α_NNP and_CC IFN-γ_NNP
        likely_JJ contribute_VB to_TO the_DT exacerbation_NN of_IN the_DT inflammatory_JJ
        conditions_NNS associated_VBN with_IN the_DT aged_VBN ._. For_IN example_NN ,_,
        autoimmune_JJ diseases_NNS are_VBP more_RBR prevalent_JJ in_IN the_DT aged_VBN ,_, where_WRB
        certain_JJ diseases_NNS such_JJ as_IN arthritis_NN are_VBP often_RB associated_VBN
        with_IN chronic_JJ debilitation_NN ._. Interestingly_RB ,_, both_DT IFN-γ_NNP and_CC
        TNF-α_NNP are_VBP prominent_JJ in_IN the_DT pathogenesis_NNS of_IN autoimmune_JJ
        diseases_NNS in_IN general_JJ ;_: the_DT former_NN by_IN activation_NN of_IN local_JJ auto_NN
        antigen_NN presentation_NN to_TO appropriate_JJ T_NN cells_NNS ,_, and_CC the_DT latter_NN
        by_IN mediation_NN of_IN inflammatory_JJ tissue_NN damage_NN [_NN 68_CD ]_NN ._.
        Apparently_RB TNF-α_NNP plays_VBZ a_DT central_JJ role_NN in_IN the_DT chronic_JJ
        release_NN of_IN highly_RB arthritogenic_JJ II-_NNP 1_CD [_NN 69_CD ]_NN ,_, and_CC thus_RB
        serves_VBZ as_IN a_DT major_JJ factor_NN in_IN the_DT pathogenesis_NNS of_IN rheumatoid_NN
        arthritis_NN (_( RA_NNP )_) [_NN 69_CD ]_NN ._. Recent_JJ studies_NNS show_VBP that_DT treatment_NN
        with_IN anti-_NN TNF-α_NNP gives_VBZ significant_JJ clinical_JJ improvement_NN in_IN
        RA_NNP [_NN 70_CD ]_NN ._. Thus_RB our_PRP$ findings_NNS in_IN aged_VBN individuals_NNS of_IN a_DT
        prominent_JJ CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN subset_NN with_IN enhanced_JJ ability_NN to_TO
        produce_VB TNF-α_NNP ,_, may_MD assume_VB clinical_JJ relevance_NN ._. It_PRP is_VBZ logical_JJ
        to_TO infer_NN that_IN the_DT increased_VBN susceptibility_NN of_IN aged_VBN
        individuals_NNS to_TO rheumatoid_NN arthritis_NN and_CC other_JJ autoimmune_JJ
        pathologies_NNS ,_, may_MD be_VB due_JJ to_TO increased_VB TNF-α_NNP (_( and_CC IFN-γ_NNP )_)
        production_NN by_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: T_NN cell_NN ._. It_PRP should_MD be_VB noted_VBN
        that_IN the_DT action_NN of_IN IFN-γ_NNP on_IN macrophages_NNS induces_VBZ TNF-α_NNP
        production_NN [_NN 61_CD ]_NN ,_, thus_RB amplifying_VBG the_DT effects_NNS of_IN the_DT
        latter_NN ._.
        Although_IN IFN-γ_NNP production_NN in_IN the_DT HIV_NNP +_NN individual_JJ by_IN the_DT
        CD_NNP 4_CD +_NN T_NN cells_NNS (_( T_NN 
        H_NNP 1_LS )_) has_VBZ been_VBN emphasized_VBN [_NN 13_CD 45_CD 49_CD ]_NN
        there_EX appears_VBZ to_TO be_VB little_JJ doubt_NN that_IN the_DT production_NN of_IN
        IFN-γ_NNP by_IN CD_NNP 8_CD +_NN CD_NNP 28_CD -_: cells_NNS may_MD have_VB greater_JJR clinical_JJ
        relevance_NN as_IN discussed_VBN above_IN on_IN the_DT increased_VBN serum_NN levels_NNS
        [_NN 45_CD 46_CD ]_NN ._. With_IN TNF-α_NNP as_IN well_RB ,_, our_PRP$ data_NNS suggest_VBP it_PRP is_VBZ
        likely_JJ that_IN the_DT increased_VBN serum_NN levels_NNS in_IN AIDS_NNP [_NN 46_CD 47_CD 48_CD ]_NN
        may_MD derive_VB in_IN part_NN from_IN increased_VBN numbers_NNS of_IN CD_NNP 8_CD +_NN CD_NNP 28_CD
        -_: cells_NNS ._. However_RB ,_, TNF-α_NNP levels_NNS could_MD also_RB originate_VB from_IN
        monocytes_NNS stimulated_VBN by_IN the_DT enhanced_VBN IFN-γ_NNP production_NN ._. In_IN
        any_DT case_NN ,_, the_DT HIV_NNP +_NN state_NN is_VBZ replete_JJ with_IN antagonistic_JJ
        complexities_NNS of_IN antiviral_JJ effects_NNS of_IN IFN-γ_NNP and_CC TNF-α_NNP on_IN one_CD
        hand_NN ,_, and_CC their_PRP$ inflammatory_JJ effects_NNS on_IN the_DT other_JJ ._. Overall_RB ,_,
        our_PRP$ data_NNS presents_VBZ an_DT intriguing_JJ parallel_NN between_IN AIDS_NNP and_CC
        the_DT aging_VBG state_NN with_IN regard_NN to_TO their_PRP$ cytokine_NN and_CC CD_NNP 8_CD +_NN T_NN
        cell_NN profiles_NNS ,_, and_CC the_DT potential_NN for_IN new_JJ insight_NN into_IN aging_VBG
        mechanisms_NNS ._. It_PRP is_VBZ noteworthy_JJ that_IN our_PRP$ results_NNS are_VBP
        compatible_JJ with_IN recent_JJ aging_NN studies_NNS using_VBG gene_NN arrays_NNS to_TO
        measure_VB gene_NN expression_NN in_IN the_DT neocortex_NN and_CC cerebellum_NN of_IN
        aged_VBN and_CC young_JJ mice_NNS ._. Lee_NNP et_CC al_NN [_NN 71_CD ]_NN found_VBD that_IN in_IN both_DT
        brain_NN regions_NNS ,_, one_CD hallmark_NN of_IN aging_VBG was_VBD enhanced_JJ gene_NN
        expression_NN of_IN the_DT inflammatory_JJ response_NN ,_, including_VBG
        proinflammatory_NN peptides_NNS and_CC many_JJ interferon-related_JJ
        proteins_NNS ._. Thus_RB the_DT advent_NN of_IN the_DT CD_NNP 8_CD +_NN CD_NNP 28_CD -_: cell_NN in_IN aging_VBG ,_,
        with_IN its_PRP$ potential_JJ for_IN proinflammatory_NN cytokines_NNS ,_, could_MD
        have_VB profound_JJ effects_NNS not_RB only_RB on_IN autoimmune_JJ diseases_NNS ,_, but_CC
        on_IN Alzheimer_NNP 's_POS disease_NN as_RB well_RB since_IN cytokines_NNS may_MD
        contribute_VB to_TO the_DT neuropathology_NN [_NN 72_CD ]_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Materials_NNS
          Con_NN A_DT ,_, phorbol_NN myristate_NN acetate_NN (_( PMA_NNP )_) ,_,
          N-_NNP acetylcysteine_NN (_( NAC_NNP )_) ,_, brefeldin_NN A_DT and_CC monensin_NN were_VBD
          obtained_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, Mo_NNP ._. )_) ,_, fetal_JJ calf_NN serum_NN
          from_IN Harlan_NNP Bioproducts_NNP (_( Madison_NNP ,_, Wis_NNP ._. )_) ,_, anti-_NN CD_NNP 28_CD and_CC
          anti-_NN CD_NNP 3_CD (_( 4_CD E_NNP )_) from_IN Research_NNP Diagnostics_NNPS (_( Flanders_NNP ,_, N_NNP ._. J_NNP ._. )_) ._.
          Purified_NNP monoclonal_NN Ab_NNP anti-_NN CD_NNP 4_CD ,_, anti-_NN CD_NNP 8_CD ,_, anti-_NN CD_NNP 14_CD and_CC
          anti-_NN CD_NNP 19_CD ,_, bound_VBN to_TO magnetic_JJ beads_NNS (_( BioMag_NNP )_) ,_, were_VBD
          obtained_VBN from_IN Perseptive_NNP Diagnostics_NNPS (_( Cambridge_NNP ,_, MA_NNP )_) ._.
          Interleukin_NNP 4_CD ,_, 8_CD ,_, 10_CD and_CC 12_CD were_VBD obtained_VBN from_IN the_DT
          Genzyme_NNP Corp_NNP ._.
        
        
          Study_NN approval_NN
          This_DT study_NN was_VBD approved_VBN by_IN the_DT Institutional_NNP Review_NNP
          Board_NNP of_IN the_DT Ponce_NNP School_NNP of_IN Medicine_NNP ,_, Ponce_NNP ,_, PR_NNP ._.
        
        
          Blood_NNP donors_NNS
          The_DT HIV_NNP +_NN population_NN (_( 32_CD donors_NNS aged_VBN 22_CD -_: 34_CD years_NNS ,_, mean_VB
          29_CD ._. 3_LS years_NNS )_) used_VBN in_IN this_DT study_NN had_VBD a_DT CD_NNP 4_CD +_NN T_NN cell_NN count_NN
          from_IN 210_CD -_: 500_CD cells_NNS /_NN mm_NN 3_CD and_CC fell_VBD in_IN the_DT A_DT 2_CD and_CC B_NNP 2_CD
          classification_NN recommended_VBN by_IN the_DT Centers_NNPS for_IN Disease_NNP
          Control_NNP ._. Most_JJS (_( 93_CD %_NN )_) of_IN the_DT HIV_NNP +_NN donors_NNS were_VBD receiving_VBG the_DT
          anti-retroviral_JJ drug_NN zidovudine_NN ._. Transmission_NNP in_IN the_DT HIV_NNP
          +_NN donors_NNS was_VBD approximately_RB 60_CD %_NN from_IN intravenous_JJ drug_NN use_NN
          and_CC 40_CD %_NN from_IN unprotected_JJ sexual_JJ activity_NN ._. Blood_NNP from_IN
          forty_NN aged_VBN individuals_NNS (_( mean_VB 84_CD ._. 2_LS years_NNS ,_, range_NN 76_CD -_: 98_CD
          years_NNS )_) was_VBD collected_VBN for_IN this_DT study_NN ._. The_DT controls_NNS (_( 48_CD
          young_JJ Hispanics_NNPS aged_VBN 19_CD -_: 30_CD years_NNS ,_, mean_VB 23_CD ._. 7_CD years_NNS ,_, from_IN
          Ponce_NNP ,_, Puerto_NNP Rico_NNP )_) ,_, had_VBD no_DT serious_JJ medical_JJ problems_NNS ._. All_DT
          donors_NNS were_VBD Hispanic_JJ ,_, blood_NN was_VBD collected_VBN from_IN HIV_NNP
          +_NN individuals_NNS (_( Hispanic_JJ )_) under_IN the_DT direction_NN of_IN Dr_NNP ._. Harold_NNP
          I_PRP ._. Laroche_NNP and_CC Dr_NNP ._. E_NNP ._. Godreau_NNP ,_, Center_NNP for_IN Diagnosis_NNP and_CC
          Treatment_NNP ,_, Ponce_NNP ._. The_DT aged_VBN population_NN ,_, recruited_VBN from_IN the_DT
          retirement_NN home_NN Los_NNP Diamantes_NNP ,_, had_VBD no_DT serious_JJ medical_JJ
          problems_NNS in_IN general_NN ._. Some_DT had_VBD minor_JJ arthritis_NN and_CC high_JJ
          blood_NN pressure_NN (_( medicated_JJ )_) ;_: one_CD had_VBD Parkinson_NNP 's_POS
          disease_NN ._.
        
        
          Purified_NNP T_NN cells_NNS
          PBMC_NNP were_VBD prepared_VBN by_IN Hypaque-_NNP Ficoll_NNP centrifugation_NN of_IN
          blood_NN diluted_VBD 1_CD :_: 1_CD with_IN PBS_NNP (_( 5_LS )_) ._. For_IN preparation_NN of_IN
          purified_JJ T_NN cells_NNS (_( CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN )_) free_JJ of_IN macrophages_NNS ,_,
          granulocytes_NNS ,_, B_NNP cells_NNS ,_, and_CC NK_NNP cells_NNS ,_, the_DT PBMC_NNP (_( 1_CD ×_NN 10_CD
          7_CD cells_NNS )_) were_VBD centrifuged_JJ ,_, and_CC diluted_VBD to_TO 200_CD ul_NN with_IN 0_CD ._. 1_CD %_NN
          BSA_NNP in_IN PBS_NNP ._. After_IN addition_NN of_IN 10_CD ul_NN of_IN fetal_JJ calf_NN serum_NN
          and_CC 10_CD ul_NN of_IN antibody_NN "_'' mix_NN "_'' (_( T_NN cell_NN negative_JJ isolation_NN
          kit_NN from_IN Dynal_NNP Inc_NNP )_) ,_, the_DT cells_NNS were_VBD incubated_JJ 10_CD minutes_NNS
          at_IN 4_CD °_NN ,_, washed_VBN in_IN PBS_NNP ,_, and_CC suspended_VBD in_IN 900_CD ul_NN PBS_NNP with_IN
          100_CD ul_NN of_IN "_'' depletion_NN "_'' beads_NNS (_( Dynal_NNP )_) ._. After_IN 15_CD minutes_NNS at_IN
          room_NN temperature_NN ,_, the_DT beads_NNS are_VBP magnetically_RB removed_VBN
          leaving_VBG highly_RB purified_JJ T_NN cells_NNS (_( CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN ,_, 98_CD %_NN
          purified_JJ in_IN general_JJ )_) ._. The_DT yield_NN varied_VBN from_IN 40_CD -_: 50_CD %_NN based_VBN
          on_IN the_DT starting_VBG number_NN of_IN PBMC_NNP ._. For_IN the_DT preparation_NN of_IN
          purified_JJ CD_NNP 4_CD +_NN T_NN cells_NNS ,_, 2_CD ×_NN 10_CD 7_CD purified_JJ T_NN cells_NNS were_VBD
          incubated_JJ for_IN 30_CD minutes_NNS on_IN ice_NN with_IN BioMag_NNP mouse_NN
          anti-human_JJ CD_NNP 8_CD (_( IgG_NNP 1_LS )_) monoclonal_NN Ab_NNP (_( 500_CD ul_NN )_) in_IN 3_CD ._. 0_CD ml_NN
          RPMI_NNP plus_CC 9_CD %_NN FCS_NNP (_( diluted_VBN 1_CD :_: 1_LS )_) for_IN 30_CD min_NN on_IN ice_NN with_IN
          rocking_VBG ._. Similarly_RB ,_, to_TO obtain_VB purified_JJ CD_NNP 8_CD +_NN T_NN cells_NNS ,_, the_DT
          same_JJ procedure_NN was_VBD followed_VBN except_IN BioMag_NNP mouse_NN
          anti-human_JJ CD_NNP 4_CD (_( IgG_NNP 2_CD a_DT )_) monoclonal_NN Ab_NNP (_( 500_CD ul_NN )_) was_VBD used_VBN ._.
          The_DT cell_NN suspension_NN was_VBD brought_VBN to_TO 10_CD ml_NN with_IN cold_JJ RPMI_NNP
          media_NNS ,_, and_CC the_DT desired_VBN T_NN cell_NN subset_NN was_VBD obtained_VBN by_IN
          magnetic_JJ removal_NN of_IN the_DT contaminating_VBG cells_NNS ._. Flow_NNP
          cytometric_JJ analysis_NN indicated_VBD that_IN the_DT T_NN cell_NN subsets_NNS
          were_VBD 93_CD -_: 98_CD %_NN purified_JJ ._. The_DT yield_NN of_IN control_NN and_CC aged_VBN cells_NNS
          varied_VBD from_IN 58_CD -_: 89_CD %_NN generally_RB ,_, whereas_IN the_DT yield_NN from_IN HIV_NNP
          +_NN blood_NN generally_RB fell_VBD between_IN 24_CD -_: 68_CD %_NN ._. Accessory_NNP cells_NNS
          were_VBD effectively_RB removed_VBN during_IN T_NN cell_NN isolation_NN as_IN shown_VBN
          by_IN the_DT failure_NN of_IN mitogen-induced_JJ proliferation_NN in_IN the_DT
          absence_NN of_IN coactivators_NNS ._. All_DT cell_NN purification_NN steps_NNS were_VBD
          completed_VBN and_CC assays_NNS initiated_VBN within_IN 10_CD hrs_NNS ._. after_IN blood_NN
          donation_NN ._. The_DT purified_JJ CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD used_VBN for_IN the_DT
          ELISA_NNP and_CC quantitative_JJ PCR_NNP studies_NNS ._.
        
        
          Flow_NNP cytometric_JJ analysis_NN (_( FC_NNP )_)
          Prior_RB to_TO FC_NNP analysis_NN ,_, PBMC_NNP (_( 3_CD ._. 3_LS ×_NN 10_CD 5_LS )_) suspended_VBN in_IN
          600_CD ul_NN media_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP overnight_JJ in_IN 6_CD %_NN CO_NNP 
          2_CD with_IN anti-_NN CD_NNP 3_CD (_( 1_CD :_: 500_CD dilution_NN of_IN
          acetates_NNS fluid_JJ )_) and_CC PMA_NNP (_( 2_CD ._. 5_LS ng_NN /_NN ml_NN )_) as_IN described_VBN
          previously_RB [_NN 25_CD ]_NN ._. Either_CC monensin_NN (_( 1_CD uM_NN )_) or_CC brefeldin_NN A_DT
          (_( 1_CD ug_NN /_NN ml_NN )_) was_VBD used_VBN in_IN all_DT cases_NNS to_TO block_VB Golgi_NNP function_NN
          and_CC allow_VB cytokine_NN accumulation_NN with_IN the_DT cell_NN ._. For_IN
          analysis_NN of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS ,_, the_DT PBMC_NNP (_( activated_VBN
          and_CC non_NN activated_VBN controls_NNS )_) were_VBD treated_VBN as_IN described_VBN by_IN
          the_DT PharMingen_NNP (_( Flow_NNP Cytometry_NNP and_CC Cell_NNP Analysis_NNP Catalog_NN
          (_( 1998_CD )_) "_'' Immunofluorescent_NNP Staining_NNP of_IN Intracellular_NNP
          Cytokines_NNP for_IN Flow_NNP Cytometric_NNP Analysis_NNP "_'' ,_, pp_NN 415_CD -_: 417_CD )_) ._.
          Briefly_NNP ,_, PBMCs_NNP were_VBD washed_VBN twice_RB with_IN staining_VBG buffer_NN
          (_( PBS_NNP plus_CC 0_CD ._. 5_CD %_NN bovine_JJ serum_NN albumin_NN )_) ,_, and_CC then_RB fixed_VBN by_IN
          suspending_VBG in_IN cold_JJ 0_CD ._. 5_CD %_NN paraformaldehyde_NN (_( PFA_NNP )_) ._. After_IN
          incubation_NN for_IN 20_CD min_NN at_IN 4_CD °_NN ,_, the_DT cells_NNS were_VBD centrifuged_JJ ,_,
          decanted_JJ and_CC resuspended_JJ in_IN 4_CD %_NN PFA_NNP for_IN 30_CD min_NN at_IN 4_CD °_NN ._.
          Cells_NNP were_VBD then_RB washed_VBN with_IN 1_CD ml_NN of_IN staining_VBG buffer_NN ,_, and_CC
          incubated_JJ 30_CD min_NN at_IN 4_CD °_NN with_IN 50_CD ul_NN permeabilization_NN buffer_NN
          (_( 0_CD ._. 1_LS %_NN saponin_NN ,_, PBS_NNP ,_, 0_CD ._. 1_CD %_NN azide_NN )_) ._. To_TO the_DT cell_NN pellet_NN ,_, 3_CD ul_NN
          of_IN phycoerythrin_NN (_( PE_NNP )_) conjugated_JJ mouse_NN anti-human_JJ IFN-γ_NNP
          or_CC TNF-α_NNP monoclonal_NN Ab_NNP (_( Pharmingen_NNP Inc_NNP ._. )_) was_VBD added_VBN and_CC
          incubated_JJ 30_CD min_NN at_IN 4_CD °_NN ._. The_DT cells_NNS were_VBD then_RB washed_VBN with_IN 1_CD
          ml_NN permeabilization_NN buffer_NN ,_, spun_VBD down_RB ,_, and_CC gently_RB
          resuspended_JJ ._. Then_RB 10_CD ul_NN of_IN fluorescein_NN isothiocyanate_NN
          (_( FITC_NNP )_) mouse_NN anti-_NN CD_NNP 8_CD (_( Leu-_NNP 2_CD a_DT )_) (_( Becton-_NNP Dickinson_NNP )_) ,_, and_CC 10_CD
          ul_NN peridinin_NN chlorophyll_NN (_( PerCP_NNP )_) mouse_NN anti-_NN CD_NNP 3_CD (_( Leu-_NNP 4_LS )_)
          (_( Becton-_NNP Dickinson_NNP )_) were_VBD added_VBN ,_, followed_VBN by_IN incubation_NN in_IN
          the_DT dark_NN for_IN 20_CD min_NN at_IN room_NN temperature_NN ._. After_IN washing_VBG
          with_IN 1_CD ml_NN of_IN staining_VBG buffer_NN ,_, the_DT cells_NNS were_VBD fixed_VBN with_IN
          600_CD ul_NN of_IN 0_CD ._. 5_CD %_NN PFA_NNP for_IN approximately_RB 1_CD day_NN and_CC then_RB
          analyzed_VBD with_IN a_DT FACSCalibur_NNP flow_NN cytometer_NN
          (_( Becton-_NNP Dickinson_NNP )_) equipped_VBN with_IN a_DT FL_NNP 4_CD channel_NN ._.
          As_IN an_DT alternative_NN to_TO FC_NNP analysis_NN of_IN activated_VBN PBMC_NNP
          described_VBD above_IN ,_, we_PRP also_RB studied_VBD activated_VBN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD
          +_NN T_NN cells_NNS purified_JJ as_IN described_VBN in_IN the_DT previous_JJ sections_NNS ._.
          These_DT studies_NNS we_PRP carried_VBD out_IN in_IN order_NN to_TO completely_RB
          eliminate_VB the_DT possibility_NN ,_, however_RB remote_JJ ,_, that_IN our_PRP$ FC_NNP
          procedure_NN did_VBD not_RB discriminate_JJ between_IN the_DT CD_NNP 8_CD +_NN T_NN cells_NNS
          and_CC NK_NNP cells_NNS ,_, which_WDT have_VBP low_JJ density_NN CD_NNP 8_CD +_NN receptors_NNS ._.
          However_RB ,_, our_PRP$ FC_NNP procedure_NN used_VBD a_DT sufficiently_RB high_JJ
          "_'' anchor_VB gate_NN "_'' to_TO examine_VB only_RB the_DT high_JJ density_NN CD_NNP 8_CD
          +_NN receptors_NNS which_WDT are_VBP uniquely_RB characteristic_NN of_IN the_DT CD_NNP 8_CD
          +_NN T_NN cell_NN ._. This_DT is_VBZ accomplished_VBN by_IN using_VBG an_DT "_'' anchor_NN gate_NN "_''
          which_WDT is_VBZ sufficiently_RB high_JJ ._. As_IN expected_VBN ,_, our_PRP$ analysis_NN of_IN
          CD_NNP 8_CD +_NN T_NN cells_NNS using_VBG either_CC the_DT purified_JJ cells_NNS or_CC the_DT PBMC_NNP
          were_VBD in_IN complete_JJ agreement_NN in_IN 5_CD experiments_NNS in_IN which_WDT they_PRP
          were_VBD compared_VBN ,_, i_NNP ._. e_SYM ._. ,_, both_DT showed_VBD the_DT same_JJ increased_VBN
          production_NN of_IN IFN-γ_NNP and_CC TNF-α_NNP from_IN HIV_NNP +_NN derived_VBN or_CC aged_VBN
          CD_NNP 8_CD +_NN T_NN cells_NNS ._.
        
        
          Analysis_NNP of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS
          Four-color_NNP cytometric_JJ analysis_NN was_VBD performed_VBN with_IN a_DT
          Power-_NNP Macintosh_NNP 7600_CD computer_NN with_IN Cellquest_NNP software_NN ._.
          Statistical_NNP analysis_NN was_VBD performed_VBN on_IN data_NNS collected_VBN from_IN
          10_CD ,_, 000_CD events_NNS (_( data_NNS points_NNS )_) per_IN cell_NN sample_NN ._. To_TO
          distinguish_VB t_NN cell_NN subsets_NNS ,_, a_DT gate_NN was_VBD drawn_VBN around_IN
          lymphocytes_NNS by_IN forward_RB scatter_NN and_CC side_NN scatter_NN (_( region_NN 1_CD
          (_( R_NN 1_LS )_) )_) ._. T_NN cells_NNS were_VBD identified_VBN as_IN a_DT CD_NNP 3_CD (_( FL_NNP 3_LS )_) positive_JJ
          population_NN (_( R_NN 2_LS )_) ,_, thereby_RB excluding_VBG CD_NNP 3_CD -_: populations_NNS such_JJ
          as_IN B_NNP cells_NNS ,_, macrophages_NNS ,_, and_CC NK_NNP cells_NNS ._. In_IN order_NN to_TO
          analyze_VB T_NN cell_NN subsets_NNS (_( CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN cells_NNS )_) for_IN each_DT
          cytokine_NN production_NN ,_, contour_NN plots_NNS on_IN CD_NNP 8_CD +_NN (_( FL_NNP 1_LS )_) /_NN
          cytokine_NN (_( FL_NNP 2_LS )_) of_IN logical_JJ gate_NN 1_CD events_NNS (_( R_NN 1_CD +_NN R_NN 2_LS )_) were_VBD
          obtained_VBN ._. The_DT event_NN numbers_NNS and_CC percentages_NNS of_IN each_DT
          quadrant_NN event_NN were_VBD recorded_VBN ._. For_IN simplicity_NN ,_, the_DT CD_NNP 3_CD
          +_NN CD_NNP 8_CD -_: T_NN cell_NN subset_NN are_VBP assumed_VBN to_TO be_VB CD_NNP 4_CD +_NN and_CC labeled_VBN as_IN
          such_JJ in_IN Fig_NNP ._. 1_LS ._. In_IN our_PRP$ experience_NN ,_, the_DT CD_NNP 3_CD +_NN CD_NNP 4_CD +_NN comprise_VBP
          95_CD %_NN or_CC more_JJR of_IN the_DT CD_NNP 3_CD +_NN CD_NNP 8_CD -_: T_NN cell_NN subset_NN in_IN normal_JJ
          blood_NN ._. In_IN HIV_NNP +_NN blood_NN ,_, a_DT few_JJ CD_NNP 4_CD +_NN T_NN cells_NNS may_MD be_VB masked_VBN by_IN
          soluble_JJ gp-_NN 120_CD ,_, but_CC this_DT would_MD not_RB affect_VB the_DT CD_NNP 3_CD +_NN CD_NNP 8_CD
          +_NN population_NN ._.
        
        
          Analysis_NNP of_IN CD_NNP 28_CD +_NN and_CC CD_NNP 28_CD -_: T_NN cells_NNS using_VBG
          four-color_JJ cytometry_NN
          For_IN this_DT study_NN ,_, PBMC_NNP were_VBD treated_VBN as_IN described_VBN above_IN
          except_IN that_DT anti-human_JJ CD_NNP 3_CD +_NN (_( FL_NNP 4_LS )_) coupled_VBN to_TO
          allophycocyanin_NN (_( APC_NNP )_) was_VBD used_VBN along_IN with_IN anti-_NN IFN-γ_NNP FITC_NNP
          (_( FL_NNP 1_LS )_) ,_, anti-_NN CD_NNP 28_CD PE_NNP (_( FL_NNP 2_LS )_) and_CC anti-_NN CDS_NNP PerCP_NNP (_( FL_NNP 3_LS )_) ._.
          Region_NNP 1_CD (_( R_NN 1_LS )_) was_VBD drawn_VBN to_TO identify_VB lymphocytes_NNS by_IN
          forward_RB scatter_NN and_CC side_NN scatter_NN ,_, and_CC R_NN 2_CD was_VBD drawn_VBN to_TO
          identify_VB T_NN cells_NNS (_( FL_NNP 4_CD positive_JJ )_) ._. Logical_NNP gate_NN 1_CD (_( R_NN 1_CD +_NN R_NN 2_LS )_)
          was_VBD used_VBN to_TO identify_VB CD_NNP 4_CD (_( FL_NNP 3_CD negative_JJ )_) and_CC CD_NNP 8_CD (_( FL_NNP 3_CD
          positive_JJ )_) subsets_NNS that_WDT were_VBD designated_VBN as_IN R_NN 3_CD and_CC R_NN 4_CD
          respectively_RB ._. Logical_NNP gate_NN 2_CD (_( R_NN 1_CD +_NN R_NN 2_CD +_NN R_NN 3_LS )_) events_NNS were_VBD
          analyzed_VBN for_IN cytokine_NN production_NN by_IN CD_NNP 28_CD +_NN (_( FL_NNP 2_LS )_) or_CC CD_NNP 28_CD
          -_: subpopulations_NNS by_IN plotting_VBG two_CD dimensional_NN contour_NN
          plots_NNS ._. Logical_NNP gate_NN 3_CD (_( R_NN 1_CD +_NN R_NN 2_CD +_NN R_NN 4_LS )_) events_NNS were_VBD similarly_RB
          analyzed_VBN ._.
        
        
          Competitive_NNP PCR_NNP
          The_DT competitive_JJ PCR_NNP was_VBD performed_VBN using_VBG both_DT IFN-γ_NNP
          mRNA_NN and_CC TNF-α_NNP mRNA_NN detection_NN kits_NNS from_IN BioSource_NNP Corp_NNP ._.
          The_DT mRNA_NN was_VBD highly_RB purified_JJ from_IN purified_JJ CD_NNP 8_CD +_NN cells_NNS
          activated_VBN for_IN 3_CD hrs_NNS ,_, with_IN the_DT Ambion_NNP RNAqueous_NNP kit_NN for_IN
          total_JJ RNA_NNP ,_, and_CC the_DT Micro_NNP Poly_NNP (_( A_DT )_) pure_JJ kit_NN for_IN mRNA_NN ._.
          Generally_RB the_DT mRNA_NN obtained_VBN was_VBD near_IN 2_CD %_NN of_IN total_JJ RNA_NNP ._. The_DT
          cDNA_NN was_VBD obtained_VBN by_IN use_NN of_IN reverse_NN transcriptase_NN
          (_( Invitrogen_NNP )_) ._. PCR_NNP was_VBD performed_VBN in_IN 100_CD ul_NN final_JJ volume_NN
          containing_VBG :_: 1_LS )_) 3_CD ul_NN of_IN IFN-γ_NNP primer_NN ;_: 2_LS )_) 18_CD ul_NN 10_CD X_NNP
          reaction_NN buffer_NN ;_: 3_LS )_) 25_CD ul_NN 200_CD uM_NN NTP_NNP 's_POS ;_: 4_LS )_) 44_CD ._. 5_LS ul_NN H_NNP 
          2_CD O_NNP ;_: 5_LS )_) 5_CD ul_NN cDNA_NN ;_: 6_CD )_) 5_CD ul_NN Internal_NNP
          Calibration_NNP Standard_NNP (_( ICS_NNP )_) DNA_NN and_CC 0_CD ._. 5_CD ul_NN Taq_NNP polymerase_NN ._.
          Components_NNP were_VBD gently_RB mixed_JJ and_CC centrifuged_JJ ,_, then_RB heated_JJ
          2_CD min_NN at_IN 95_CD °_NN ._. Thirty_NNP cycles_NNS were_VBD performed_VBN with_IN a_DT Perkin_NNP
          Elmer_NNP 9600_CD thermocycler_NN as_IN follows_VBZ :_: 1_CD min_NN at_IN 95_CD °_NN ,_, 1_CD min_NN
          at_IN 55_CD °_NN ,_, 1_CD min_NN at_IN 72_CD °_NN ._. The_DT reaction_NN was_VBD next_JJ heated_JJ at_IN 72_CD °_NN
          for_IN 10_CD min_NN following_VBG by_IN cooling_VBG at_IN 4_CD °_NN ._. A_DT 15_CD ul_NN sample_NN
          from_IN each_DT PCR_NNP reaction_NN was_VBD analyzed_VBN on_IN 2_CD %_NN agarose_NN gels_NNS
          containing_VBG 0_CD ._. 5_CD ug_NN /_NN ml_NN ethidium_NN bromide_NN along_IN with_IN
          molecular_JJ weight_NN standards_NNS to_TO determine_VB the_DT fragment_NN
          size_NN ._. Bands_NNP were_VBD visualized_JJ under_IN UV_NNP light_JJ and_CC
          photographed_VBN using_VBG Polaroid_NNP film_NN ._.
          After_IN cDNA_NN amplification_NN ,_, 25_CD ul_NN of_IN PCR_NNP mix_NN was_VBD removed_VBN
          and_CC transferred_VBN to_TO a_DT microcenterfuge_NN tube_NN ._. The_DT same_JJ
          volume_NN of_IN denaturation_NN solution_NN (_( alkaline_NN pH_NN )_) was_VBD added_VBN
          to_TO the_DT tube_NN and_CC incubated_JJ for_IN 10_CD min_NN at_IN room_NN temperature_NN ._.
          The_DT material_NN was_VBD neutralized_VBN by_IN the_DT addition_NN of_IN 450_CD ul_NN of_IN
          hybridization_NN solution_NN prior_RB to_TO addition_NN to_TO the_DT ICS_NNP or_CC
          IFN-γ_NNP oligonucleotide_NN capture_NN wells_NNS (_( OCW_NNP )_) ._. In_IN order_NN to_TO
          acquire_VB quantitative_JJ results_NNS the_DT denatured_JJ amplicons_NNS were_VBD
          analyzed_VBN at_IN 1_CD /_NN 20_CD ,_, 1_CD /_NN 100_CD ,_, 1_CD /_NN 200_CD dilution_NN in_IN hybridization_NN
          buffer_NN ._.
          Following_VBG hybridization_NN ,_, unbound_NN material_NN was_VBD removed_VBN
          by_IN washing_VBG the_DT wells_NNS four_CD times_NNS with_IN 200_CD ul_NN diluted_VBN wash_VB
          buffer_NN ;_: 100_CD ul_NN of_IN streptavidin_NN -_: HPR_NNP was_VBD then_RB added_VBN to_TO
          each_DT well_RB and_CC incubated_JJ for_IN 30_CD min_NN at_IN room_NN temperature_NN ._.
          The_DT wells_NNS were_VBD washed_VBN again_RB ,_, and_CC 100_CD ul_NN of_IN stabilized_VBN
          chromogen_NN (_( substrate_NN )_) was_VBD added_VBN ._. After_IN a_DT 30_CD minute_NN
          incubation_NN in_IN the_DT dark_NN ,_, the_DT reaction_NN was_VBD stopped_VBN by_IN
          addition_NN of_IN 100_CD ul_NN stop_NN solution_NN and_CC the_DT observance_NN was_VBD
          measured_VBN at_IN 450_CD nm_NN ._. The_DT optical_JJ density_NN (_( OD_NNP )_) in_IN each_DT well_RB
          is_VBZ proportional_JJ to_TO the_DT amount_NN of_IN amplicon_NN present_NN ,_, which_WDT
          can_MD be_VB related_VBN to_TO the_DT copy_NN number_NN of_IN either_DT ICS_NNP or_CC IFN-γ_NNP
          in_IN the_DT original_JJ PCR_NNP reaction_NN ._. The_DT total_JJ OD_NNP is_VBZ calculated_VBN
          as_IN sample_NN OD_NNP multiplied_VBN by_IN the_DT amplicon_NN dilution_NN ._. The_DT
          number_NN of_IN copies_NNS of_IN IFN-γ_NNP in_IN each_DT PCR_NNP reaction_NN are_VBP
          calculated_VBN from_IN the_DT ratio_NN of_IN total_JJ OD_NNP for_IN the_DT IFN-γ_NNP
          specific_JJ well_RB to_TO the_DT total_JJ OD_NNP for_IN the_DT ICS_NNP well_RB times_NNS the_DT
          and_CC input_NN copies_NNS of_IN the_DT ICS_NNP ._.
        
        
          ELISA_NNP
          The_DT IFN-γ_NNP and_CC TNF-α_NNP secreted_JJ by_IN CD_NNP 8_CD +_NN T_NN cells_NNS into_IN
          culture_NN media_NNS was_VBD quantitated_JJ using_VBG an_DT Elisa_NNP kit_NN from_IN
          either_DT BioSource_NNP (_( Corp_NNP ._. )_) or_CC Research_NNP Diagnostics_NNPS ._. The_DT CD_NNP 8_CD
          +_NN T_NN cells_NNS were_VBD incubated_JJ at_IN 37_CD °_NN for_IN 66_CD hours_NNS in_IN precisely_RB
          the_DT same_JJ way_NN as_IN for_IN mitogenic_JJ assay_NN except_IN volumes_NNS were_VBD
          doubled_VBN and_CC 50_CD ,_, 000_CD cells_NNS were_VBD used_VBN ._. Samples_NNP were_VBD run_VBN in_IN
          duplicate_VB ,_, the_DT results_NNS were_VBD highly_RB reproducible_JJ (_( S_NNP ._. D_NNP ._.
          <_NN 15_CD %_NN for_IN any_DT given_VBN assay_NN )_) and_CC sensitive_JJ ._. However_RB ,_,
          sensitivity_NN was_VBD not_RB important_JJ since_IN with_IN most_JJS samples_NNS it_PRP
          was_VBD necessary_JJ to_TO dilute_VB the_DT culture_NN fluid_JJ by_IN 1_CD :_: 20_CD or_CC
          more_JJR ._. The_DT procedure_NN was_VBD followed_VBN as_IN recommended_VBN by_IN the_DT
          manufacturer_NN ._. The_DT standard_JJ curves_NNS for_IN IFN-γ_NNP and_CC TNF-α_NNP ,_,
          which_WDT intersected_JJ the_DT origin_NN ,_, was_VBD generally_RB linear_JJ up_IN to_TO
          500_CD pg_NN /_NN ml_NN for_IN recombinant_JJ IFN-γ_NNP and_CC 400_CD pg_NN /_NN ml_NN for_IN
          TNF-α_NNP ._.
        
      
    
  
